Sabuwar Hayar Rayuwa: Nasarar CD7 CAR-T Therapy Bridges don dashen ga yaro ɗan shekara 15 tare da T-ALL da ya koma baya

Yana ɗan shekara 15 kacal, rayuwar wani yaro ta canza sakamakon gano cutar sankarar lymphoblastic mai tsanani ta T-cell (T-ALL), wadda aka yi wa alama da wasu matsaloli da kuma koma-baya. Duk da cewa an yi masa maganin chemotherapy da kuma dashen ƙwayoyin halitta na allogeneic, ya fuskanci koma-baya da kuma matsaloli da wuri. Duk da haka, ta hanyar sadaukarwar iyalinsa da ƙwarewar ƙungiyar likitoci a BIOOCUS, ya sami maganin CD7 CAR-T, wanda daga ƙarshe ya kai ga yin dashen na biyu wanda zai ceci rai.

Da farko an gano cutar a watan Disamba na 2020, majinyacin ya sami cikakkiyar sauƙi bayan zagaye da dama na maganin chemotherapy. Duk da haka, watanni uku kacal bayan dashen, ya sake komawa, wanda ya ƙara ta'azzara sakamakon shiga cikin tsarin jijiyoyi na tsakiya. Magungunan da aka saba amfani da su sun gaza, wanda ya bar iyalin suna neman wasu hanyoyin.

A watan Oktoban 2021, an kwantar da majinyacin a BIOOCUS, inda aka ƙara masa maganin chemotherapy don rage nauyin ƙari kafin a yi masa magani da ƙwayoyin CAR-T na CD7. Abin takaici, ƙoƙarin farko na CAR-T bai yi nasara ba, wanda ya sa ƙungiyar likitoci ta yi la'akari da gwajin asibiti da ake ci gaba da yi don maganin CAR-T na CD7.

Maganin CAR-T na duniya yana ba da fa'idodi masu yawa, gami da ikon amfani da ƙwayoyin T da aka samo daga masu ba da gudummawa masu lafiya, wanda ke ba da damar samun magani cikin sauri ba tare da buƙatar keɓancewa na musamman ba. Wannan yana da mahimmanci ga majiyyaci, wanda ke da nauyin ƙari mai yawa kuma ba zai iya samar da isassun ƙwayoyin halitta don maganin CAR-T na gargajiya ba.

A ranar 2 ga Disamba, 2021, majiyyacin ya karɓi ƙwayoyin CAR-T na CD7 na duniya baki ɗaya. Bayan an yi masa magani, da farko ya fuskanci ƙalubale, ciki har da zazzabi da gajiya. Duk da haka, tare da kulawa mai kyau, yanayinsa ya daidaita, kuma gwaje-gwajen da aka yi masa sun nuna cikakkiyar sassauci, ba tare da wata shaida ta ƙarancin sauran cututtuka ba (MRD).

Bayan wannan nasarar da aka samu, majiyyacin ya sake yin dashen jiki, wanda ya tafi cikin sauƙi. Yanzu, kusan shekaru uku bayan haka, yana samun ci gaba, yana ci gaba da ayyukansa na yau da kullun kuma yana jin daɗin rayuwa, wanda hakan ya faranta wa iyalinsa rai sosai.

Dr. Zhang Xian, shugaban sashen kula da cututtukan jini a BIOOCUS, ya jaddada muhimmancin maganin CD7 na duniya baki daya CAR-T a matsayin muhimmin zaɓi ga marasa lafiya da ba za su iya yin maganin gargajiya ba. Wannan shari'ar ta nuna makomar da za a samu nan gaba wajen magance cututtukan T-cell, musamman ga wadanda ke fama da cutar sankarar jini da ta sake dawowa.

Yayin da bincike ke ci gaba, yuwuwar magungunan CAR-T na ci gaba da faɗaɗa, wanda ke ba wa marasa lafiya da ke fama da ƙalubale kamar T-ALL sabon bege. BIOOCUS ya ci gaba da jajircewa wajen fara sabbin magunguna da inganta sakamakon marasa lafiya ta hanyar ci gaba da binciken asibiti.

Don ƙarin bayani game da magungunan CAR-T da kuma yadda za su iya taimaka maka ko ƙaunataccenka, tuntuɓi BIOOCUS.